The Latest Breaking News from Compass

Florian Brand's Atai Life Sciences went public three years after launching, fueled by Silicon Valley interest and promising science, but it's still waiting for its first big breakthrough.

Higher costs for the business have been offset by a number of new contracts

Public sector borrowing in October stood at £13.5 billion, a much smaller figure than the City had expected.

Gainers Snail, Inc. (NASDAQ: SNAL) shares jumped 74.9% to $3.9350 after the company announced a $5 million share repurchase program.

A psilocybin-based drug for treatment-resistant depression may be one step closer to approval, researchers say.

Psychedelics mental healthcare firm COMPASS Pathways (NASDAQ: CMPS) reported its financial outcomes for the third quarter ended 30 September 2022 and gave an update on its most recent pipeline and business developments.

The Cannabis ETF (ARCA: THCX) is down roughly 62% year-to-date, as emerging markets have received the biggest brunt of the market downfall since the beginning of the year.

Compass Studio is a Sydney based boutique PR & Marketing agency that specialises in conscious brands in a bid to ‘do good work, for brands that do good.’ Through a love of community, nature and a passion for purpose-driven business, Compass has created a unique agency-model that has gained fast…

Psychedelics biotech company Compass Pathways (NASDAQ: CMPS) announced it will conduct two separate Phase 3 clinical trials to study psilocybin-assisted therapy on Treatment-Resistant Depression (TRD), 

Its advocates range from Tim Berners-Lee to Pope Francis, while Andy Burnham has said he’d like to see it trialled in Greater Manchester. So could UBI be an idea whose time has come?

We’ve found studios and one-bedroom flats in every London borough, all well below the £526,000 average cost of a home in the capital. But be warned, they’re all tiny.